Aquestive Therapeutics (AQST) Reiterated at Market Outperform by Citizens Before FDA Meet

March 6, 2026 4:38 AM EST Send to a Friend
Citizens analyst Jason Butler reiterated a Market Outperform rating and $10.00 price target on Aquestive Therapeutics (NASDAQ: AQST).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login